학술논문
PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France
Document Type
Abstract
Author
Source
In Value in Health December 2020 23 Supplement 2:S433-S433
Subject
Language
ISSN
1098-3015